alexa Modeling BRAF Inhibitor Resistance In Melanoma Reveals A Strategy To Forestall Drug Resistance | 15978
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd World Congress on Cancer Science & Therapy

Martin McMahon, Meghna Das Thakur, Fernando Salansang, Allison Landman, William R. Sellers, Nancy K. Pryer, Mitchel P. Levesque, Reinhard Dummer, Rosalie Fisher, Martin Larkin and Darrin Stuart
Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.030
Abstract
Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, with >50% of tumors expressing the BRAFV 600E oncoprotein. Moreover, the marked tumor regression and improved survival of late stage BRAF-mutated melanoma patients in response to treatment with vemurafenib demonstrates the essential role of oncogenic BRAF in melanoma maintenance. However, since most patients relapse with lethal drug resistant disease, understanding and preventing mechanism(s) of resistance is critical to providing improved therapy. To that end we investigated the causes and consequences of vemurafenib resistance using two independent primary human patient-derived melanoma xenograft models in which drug resistance is selected by continuous vemurafenib administration. In one of these models, resistant tumors show continued dependency on BRAFV 600E →MEK→ERK signaling due to elevated BRAFV 600E expression. Most importantly, we demonstrate that vemurafenib- resistant melanomas become drug dependent for their continued proliferation, such that cessation of drug administration leads to regression of established drug-resistant tumors. We further demonstrate that a discontinuous dosing strategy, which exploits the fitness disadvantage displayed by drug resistant cells in the absence of the drug, forestalls the onset of lethal drug-resistant disease. These data highlight the concept that drug resistant cells may also display drug dependency, such that altered dosing may prevent the emergence of lethal drug resistance. Such observations may contribute to sustaining the durability of the response of melanomas to BRAF inhibitor therapy with the ultimate goal of curative therapy for the subset of BRAF mutated melanoma patients.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7